Carfilzomib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
peginesatide
Erythropoiesis-Stimulating Agent · Hematopoietic Agent
Erythropoiesis-Stimulating AgentHematopoietic Agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
4 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- CarfilzomibSevereDatabaseDDInter
- LenalidomideSevereDatabaseDDInter
- PomalidomideSevereDatabaseDDInter
- ThalidomideSevereDatabaseDDInter
Mechanism
Peginesatide is an erythropoiesis-stimulating peptide, identified and developed based on phage display technology and coupled to polyethylene glycol, which acts as an agonist of the erythropoietin receptor.
Indications
anemia due to chronic kidney disease
Side effects
Serious
- serious hypersensitivity reactions
- anaphylaxis
Drug interactions
Lenalidomide
Severe
Database
Clinical effect not specified
Source: DDInter
Pomalidomide
Severe
Database
Clinical effect not specified
Source: DDInter
Thalidomide
Severe
Database
Clinical effect not specified
Source: DDInter
8 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Chronic kidney disease — assessment and management
NICE · Nephrology · 2021
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022
Hypertension in chronic kidney disease
KDIGO · Nephrology · 2021
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Other Erythropoiesis-Stimulating Agent drugs
Ask House about peginesatide
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team